IMPORTANT NOTICE: At Fortis Healthcare, we are fully supportive of the National priorities set out by the Hon’ble Prime Minister of India. Further to the directives of the Government provided in their press release dated 8th Nov 2016, payments at Government hospitals can be made through 500 and 1000 Rupee denomination notes. In view of the hardship being caused to the large number of patients at private hospitals, we have made an urgent representation to the Government that this exemption should apply equally, for payments, at private hospitals. We are following up with the authorities and hope the Government will step in quickly to resolve this anomaly. Meanwhile, at Fortis hospitals across the country, we continue to accept payments through credit card, debit card and electronic banking transfers. As 500 and 1000 Rupee denomination notes are no longer legal tender we are only accepting 100 Rs and lower currency notes. As per Government regulation, a PAN card and legitimate ID proof is however required for payments in cash exceeding Rs 50,000. Meanwhile we continue to ensure that emergency cases get immediate medical attention without delay whatsoever and have put in more administrative staff and help desks to assist patients.

Doctor Profile

Dr. Tejinder Singh

Dr. Tejinder Singh, DM

8+ Years Of Experience

Consultant, Medical Oncology Fortis Hospital, Mulund

Oncology

OPD Schedule - +91 22 4365 4365

DM (Medical Oncology), Kidwai Memorial Institute of Oncology

Dr. Tejinder Singh is working with Fortis Hospitals, Mulund as a medical oncologist & hemato-oncologist. He has undergone training in medical oncology from Kidwai Memorial Institute of Oncology, Bangalore, a premier institute for cancer treatment.He has experience in the management of immunocompromised patients, adminstration of chemotherapeutic agents for haematological and solid tumors and managing their toxicities.He was actively involved in stem cell related activities in his institute and has done at least 20 autologous bone marrow transplantations. He has undergone an advanced training in “Essentials of Palliative Care” and has been part of multiple phase I, II, III clinical trials also.